Signaling via ErbB2 and ErbB3 Associates with Resistance and <i>Epidermal Growth Factor Receptor</i> (<i>EGFR</i>) Amplification with Sensitivity to EGFR Inhibitor Gefitinib in Head and Neck Squamous Cell Carcinoma Cells

Erjala, Kaisa; Sundvall, Maria; T. Junttila, Teemu; Zhang, Na; Savisalo, Mika; Mali, Pekka; Kulmala, Jarmo; Pulkkinen, Jaakko; Grénman, Reidar; Elenius, Klaus

doi:10.1158/1078-0432.ccr-05-2404

Public

Signaling via ErbB2 and ErbB3 Associates with Resistance and Epidermal Growth Factor Receptor (EGFR) Amplification with Sensitivity to EGFR Inhibitor Gefitinib in Head and Neck Squamous Cell Carcinoma Cells

Published in Clinical Cancer Research • Jul 1, 2006

Authors:

Kaisa Erjala

Maria Sundvall

Teemu T. Junttila

Abstract

PURPOSE: The epidermal growth factor receptor (EGFR) inhibitor gefitinib (Iressa) has shown antitumor activity in clinical trials against cancers, such as non-small cell lung cancer and head and neck squamous cell carcinoma (HNSCC). Research on non-small cell lung cancer has elucidated factors that ...

Subject

Gefitinib

Cetuximab

Epidermal growth factor receptor

Research Assistant

AI chat, annotations, notes & similar papers

Finding related papers...

Discussions

(0)

No comments yet

Be the first to share your thoughts!